HowlandECrosswellMD

Pediatric Hematology & Oncology • Greenville, SC

Physician

Join to view full profile

Are you Dr. Crosswell?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 56 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
900 W Faris Rd
2ND floor
Greenville, SC 29605
Phone+1 864-455-8898

Fax+1 864-455-5164
Is this information wrong?

Summary

Dr. Howland Crosswell, MD is a pediatric hematologist/oncologist in Greenville, South Carolina. He is currently licensed to practice medicine in South Carolina, West Virginia, and North Carolina. He is affiliated with Bon Secours St. Francis Health System.

Education & Training

Emory University School of MedicineFellowship, Pediatric Hematology/Oncology, 2006
University of Louisville School of MedicineResidency, Pediatrics, 1997 - 2000
Medical University of South CarolinaClass of 1997

Certifications & Licensure

NC State Medical License 2014 - 2025
SC State Medical License 2000 - 2025
WV State Medical License 2015 - 2016
GA State Medical License 2003 - 2007
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
3D Prediction of Patient-Specific Response Start of enrollment: 2018 Jun 11
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, David J Straus, Kerry J Savage, Pier Luigi Zinzani, Graham P Collins, Michelle Fanale, Keenan Fenton, Cassie Dong...> ;Haematologica. 2024 Mar 1
1 citations
Comparing Barriers and Facilitators to Adolescent and Young Adult Clinical Trial Enrollment Across High- and Low-Enrolling Community-Based Clinics.
Elizabeth J Siembida, Holli A Loomans-Kropp, Irene Tami-Maury, David R Freyer, Lillian Sung, Howland E Crosswell, Brad H Pollock, Michael E Roth> ;The Oncologist. 2022 May 6
16 citations
Barriers and Facilitators to Adolescent and Young Adult Cancer Trial Enrollment: NCORP Site Perspectives.
Elizabeth J. Siembida, Holli A. Loomans-Kropp, Irene Tamí-Maury, David R. Freyer, Lillian Sung, Howland E Crosswell, Brad H. Pollock, Michael Roth> ;JNCI Cancer Spectrum. 2021 Mar 22
12 citations
Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay
Stephen Shuford, Lindsay Lipinski, Ajay Abad, Ashley M. Smith, Melissa Rayner, Lauren J. O'Donnell, Jeremy Stuart, Laszlo Mechtler, Andrew J. Fabiano, Jeff Edenfield, ...> ;Neuro-Oncology Advances. 2021 Jan 1
24 citations
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expres...
Alison Walker, John C. Byrd, James S. Blachly, Bhavana Bhatnagar, Alice S. Mims, Shelley Orwick, Tara L. Lin, Howland E. Crosswell, Danjie Zhang, Mark D. Minden, Veere...> ;Clinical Cancer Research. 2020 Nov 15
4 citations
Complete Response to Dual Immunotherapy in a Young Adult with Metastatic Alveolar Soft Part Sarcoma Enabled by a Drug Recovery Program in a Community Practice.
Alexandra Conry, Melissa Peters, Daniel B Fried, Amy Adams, Alfred W Campbell, James D. Bearden, Robert D. Siegel, Howland E. Crosswell> ;Journal of Adolescent and Young Adult Oncology. 2020 Jun 8
21 citations
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Beh...> ;British Journal of Haematology. 2020 Feb 12
36 citations
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.
Stephen Shuford, Christine Wilhelm, Melissa Rayner, Ashley Elrod, Melissa Millard, Christina Mattingly, Alina Lotstein, Ashley M. Smith, Qi Jin Guo, Lauren O’Donnell, ...> ;Scientific Reports. 2019 Aug 1
2 citations
Drug Recovery and Copay Assistance Program in a Community Cancer Center: Charity and Challenges.
Robert D. Siegel, Richard Slough, Howland E. Crosswell, Theresa M Standifer, Michael Borron, Dionne Pringle, Karen K Hancock, Lara H Widener, Erin B Hill, Terra F Span...> ;Journal of Oncology Practice. 2019 Jun 4
155 citations
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Beh...> ;Blood. 2018 Jul 5
2 citations
Trials and Tribulations for Adolescents and Young Adults with Cancer: Measuring the Impact of a Community-Based Program.
Howland E. Crosswell, Kaitlin Bomar, Nicole Vickery, Kristina Stoeppler-Biege, Terra Spann, Robert D. Siegel> ;Journal of the National Comprehensive Cancer Network. 2017 Sep 1
38 citations
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
Shashikant Srivastava, Jotam G. Pasipanodya, Geetha Ramachandran, Devyani Deshpande, Stephen Shuford, Howland E. Crosswell, Kayle N Cirrincione, Carleton M. Sherman, S...> ;Ebiomedicine. 2016 Apr 1
34 citations
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
Hal E. Crosswell, Anindya Dasgupta, Carlos S. Alvarado, Tanya C. Watt, James G. Christensen, Pradip De, Donald L. Durden, Harry W. Findley> ;BMC Cancer. 2009 Nov 25
2 citations
Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
Howland E. Crosswell, Daniel John Bergsagel, Robert B. Yost, Glen Lew> ;Pediatric Blood & Cancer. 2008 Apr 1
Join now to see all

Press Mentions

Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRISDecember 2nd, 2018

Hospital Affiliations

Bon Secours St. Francis Health SystemGreenville, South Carolina